Abstract
Aim: Compare thrombotic risk in people with congenital hemophilia A (PwcHA) to the general non-hemophilia A (HA) population. Patients & methods: US claims databases were analyzed to identify PwcHA. Incidence rates of myocardial infarction, pulmonary embolism, ischemic stroke, deep vein thrombosis and device-related thrombosis were compared with a matched cohort without HA. Results: Over 3490 PwcHA were identified and 16,380 individuals matched. PwcHA had a similar incidence of myocardial infarction and pulmonary embolism compared with the non-HA population, but a slightly higher incidence of ischemic stroke and deep vein thrombosis. The incidence of device-related thrombosis was significantly higher in PwcHA. Conclusion: This analysis suggests that PwcHA are not protected against thrombosis, and provides context to evaluate thrombotic risk of HA treatments.Tweetable abstract People with #hemophilia A are not protected against thrombotic events and should be monitored for thrombotic risk factors; the thrombotic risk of hemophilia A treatments should also be evaluated.
Original language | English |
---|---|
Pages (from-to) | 1323-1336 |
Number of pages | 14 |
Journal | Journal of Comparative Effectiveness Research |
Volume | 10 |
Issue number | 18 |
Early online date | 22 Oct 2021 |
DOIs | |
Publication status | Published - Oct 2021 |
Keywords
- hemophilia A
- hemostasis
- ischemic stroke
- myocardial infarction
- pulmonary embolism
- therapeutics
- thrombosis
- vascular access devices
- venous thrombosis
- VENOUS ACCESS DEVICES
- FACTOR-VIII
- CARDIOVASCULAR-DISEASE
- EMICIZUMAB
- PROPHYLAXIS